Abstract: The present invention relates to stabilized formulations for parenteral administration comprising a therapeutically effective amount of levomepromazine or a pharmaceutically acceptable salt thereof, and selected stabilizers in an amount effective to stabilize said formulation, to stable terminally sterilized levomepromazine formulations, to methods stabilizing pharmaceutical formulations comprising levomepromazine, and to methods of treating disorders using said formulation.
Abstract: A pharmaceutically active N-desmethyl levomepromazine (abbreviated NDM LMP) and method of use. NDM LMP has substantially the same therapeutic effects as the parent levomepromazine but is subject to less disposition (e.g. presystemic and systemic metabolism) and thus has improved properties over the parent.
Abstract: An infusor system for administering medications to a venous blood vessel in the body of a patient. The infusor system includes a flexible, elongated delivery tube having opposite ends. One of the ends is couplable to a supply of liquid medication, which is remote from the venous blood vessel. The system further includes a delivery component coupled to the other end of the delivery tube. This delivery component is adaptable to be placed in confronting relationship with the venous blood vessel so that medication from said supply may be introduced directly into the venous blood vessel and distributed in the body of the patient. The infusor system further includes a pressure-altering device used for increasing intraabdominal pressure in the body of the patient. Sampling of venous blood from the meningorrhachidian vasculature is also possible.
Abstract: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.
Type:
Application
Filed:
July 31, 2003
Publication date:
February 3, 2005
Applicant:
Xanodyne Pharmacal, Inc.
Inventors:
Ralph Heasley, Keith Moore, Jeffrey Greiwe
Abstract: Compositions and methods for parenterally administering methadone. The methadone composition may be administered in a sterile, preservative-free formulation, or in a formulation including a chlorobutanol-free, government approved preservative. The methadone formulations are administered parenterally, such as intravenously or topically, for many applications including the treatment of pain resulting from chronic disorders, cancer, acute symptoms and the like.
Type:
Application
Filed:
March 14, 2003
Publication date:
September 16, 2004
Applicant:
Xanodyne Pharmacal, Inc.
Inventors:
Gilbert R. Gonzales, James L. Young, Ralph A. Heasley, Paolo L. Manfredi
Abstract: A system and method for cooling and warming the central nervous system of a patient comprises a delivery tube with one of the ends couplable to a supply of fluid. A head structure is coupled to the other end of the delivery tube and cooling or warming fluid is directed through the tube to the head structure. The head structure is configured to be placed within the rectal cavity of a patient such that either a contact surface on the head structure or the fluid itself directly contacts a portion of the rectal mucosal membrane. A means for reversing the vertebral venous flow of blood through Batson's plexus supplies cooled or warmed blood directly to the vertebral structures. Unique methods of utilizing the system to selectively cool and warm the central nervous system structures of a patient are set forth herein.
Abstract: Compositions and method including a visual marker for monitoring patient compliance with a medication regimen. The marker is formulated with a rapid dissolve layer and adhered to, or ingested with, an orally administrable medicament. Upon ingestion, the marker is released causing a detectable marker-induced property in the oral and/or pharyngeal cavity of a subject. By examining the patient's oral and/or pharyngeal cavity and articles associated with the patient, one can determine whether the medicament has been ingested based upon the presence or absence of the property. The composition is also useful for tracking the location of an un-ingested medicament.
Type:
Application
Filed:
March 26, 2003
Publication date:
October 16, 2003
Applicant:
Xanodyne Pharmacal, Inc.
Inventors:
Ralph A. Heasley, Gilbert R. Gonzales, Roger D. Griggs